No benefit for TS-1/irinotecan combo in second-line gastric cancer
This article was originally published in Scrip
Adding Taiho Pharmaceutical's TS-1 to irinotecan for the second-line treatment of gastric cancer patients refractory to first-line TS-1 therapy confers no survival benefit over irinotecan alone, new summary results from a Japanese Phase III trial show.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.